Uveal melanoma

Kashyap, Seema; Meel, Rachna; Singh, Lata; Singh, Meharban

doi:10.1053/j.semdp.2015.10.005

Cited by 26 publications

(21 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uveal melanoma (UM) is the most common type of malignant tumor in adult eyes, and 50% of UM patients will eventually die for their disease [1][2][3]. Although there are certain advances in the diagnosis and treatment of UM, the prognosis for patients with UM remains poor [4].…”

Section: Introductionmentioning

confidence: 99%

Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma

Wan

Sang

Jin

et al. 2020

Genes

View full text Add to dashboard Cite

Growing evidence has revealed that abnormal alternative splicing (AS) events are closely related to carcinogenic processes. However, the comprehensive study on the prognostic value of splicing events involved in uveal melanoma (UM) is still lacking. Therefore, splicing data of 80 UM patients were obtained from the Cancer Genome Atlas (TCGA) SpliceSeq and RNA sequence data of UM and patient clinical features were downloaded from the Cancer Genome Atlas (TCGA) database to identify survival related splicing events in UM. As a result, a total of 37996 AS events of 17911 genes in UM were detected, among which 5299 AS events of 3529 genes were significantly associated with UM patients’ survival. Functional enrichment analysis revealed that this survival related splicing genes are corelated with mRNA catabolic process and ribosome pathway. Based on survival related splicing events, seven types of prognostic markers and the final overall prognostic signature could independently predict the overall survival of UM patients. Finally, an 11 spliced gene was identified in the final signature. On the basis of these 11 genes, we constructed a Support Vector Machine (SVM) classifier and evaluated it with leave-one-out cross-validation. The results showed that the 11 genes could determine short- and long-term survival with a predicted accuracy of 97.5%. Besides, the splicing factors and alternative splicing events correlation network was constructed to serve as therapeutic targets for UM treatment. Thus, our study depicts a comprehensive landscape of alternative splicing events in the prognosis of UM. The correlation network and associated pathways would provide additional potential targets for therapy and prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma

Wan

Sang

Jin

et al. 2020

Genes

View full text Add to dashboard Cite

show abstract

“…3 In recent years, the local control of the tumor has been an effective option in the treatment of uveal melanoma; however, half of these patients end up with advanced metastatic disease within 15 years. 4 Long noncoding RNAs (lncRNAs) have been shown to play a role in the initiation and growth of the tumor owing to their ability to regulate chromatin organization, transcription, and posttranscription by modulating protein molecules, DNA, RNA, and/or their combinations. 5 In this study, the involvement of lncRNA plasmacytoma variant translocation 1 gene (PVT1) and microRNA-17-3p (miR-17-3p) in uveal melanoma tumorigenesis and development, and the underlying mechanism, were investigated.…”

mentioning

confidence: 99%

Long Noncoding RNA PVT1 Silencing Prevents the Development of Uveal Melanoma by Impairing MicroRNA-17-3p–Dependent MDM2 Upregulation

Chen

Han

Zhang

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. Uveal melanoma is a common primary intraocular malignancy accompanied by high mortality. Previous evidence has highlighted the implication of microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) in uveal melanoma. Accordingly, we further uncovered the possible role of lncRNA plasmacytoma variant translocation 1 gene (PVT1) and microRNA-17-3p (miR-17-3p) in uveal melanoma. METHODS. A series of experiments were performed to examine the relationship among lncRNA PVT1, miR-17-3p, and murine double minute clone 2 oncoprotein (MDM2). Afterward, gain-and loss-of-function approaches were used with uveal melanoma cells to verify the role of lncRNA PVT1, miR-17-3p, and MDM2 in the tumorigenesis and development of uveal melanoma. RESULTS. Highly expressed lncRNA PVT1 and MDM2, yet lowly expressed miR-17-3p, were identified in ocular uveal melanoma tissues versus normal adjacent tissues. Then, dual luciferase reporter gene assay, RNA binding protein immunoprecipitation, and RNA pull-down assays showed that lncRNA PVT1 specifically bound to miR-17-3p, and that MDM2 was a target gene of miR-17-3p. Gain-and loss-of-function studies elucidated that silencing of lncRNA PVT1 or overexpression of miR-17-3p resulted in decreased MDM2 expression and increased transcriptional activity of p53, in addition to inhibiting uveal melanoma cell proliferation, migration, and invasion, yet promoted cell apoptosis in vitro. In addition, lncRNA PVT1 silencing or miR-17-3p overexpression was noted to inhibit tumor growth in vivo. CONCLUSIONS. Downregulation of lncRNA PVT1 could potentially promote miR-17-3p expression to suppress tumorigenesis and development of uveal melanoma by activating the p53 signaling pathway through binding to MDM2.

show abstract

“…Although most melanoma tumors develop in the skin (cutaneous melanoma), they can also arise in mucosal membranes, [10][11][12][13][14][15][16][17], in the eye (uveal melanoma) [18], and primary melanoma tumors have also been described in leptomeninges (Table 1) [19]. Among these different types of melanoma, cutaneous melanoma is by far the most prevalent.…”

Section: Cutaneous and Non-cutaneous Melanomamentioning

confidence: 99%

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

View full text Add to dashboard Cite

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

show abstract

Uveal melanoma

Cited by 26 publications

References 69 publications

Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma

Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma

Long Noncoding RNA PVT1 Silencing Prevents the Development of Uveal Melanoma by Impairing MicroRNA-17-3p–Dependent MDM2 Upregulation

RAGE Signaling in Melanoma Tumors

Contact Info

Product

Resources

About